Ixekizumab

依奇珠单抗

Report date: 2026/03/23 20:03:44

Base Information

Drug NameIxekizumab
Drug Alias NameIL-17 Ab艾塞吉珠单抗艾克司单抗IL-17 antibodyInterleukin 17 antibody +[14] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin 17A inhibitors
TargetsInterleukin 17A
Therapy Area/IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisIdiopathic Subglottic Stenosis +[15] 
Global Approved IndicationsPlaque psoriasisPsoriasisArthritis, Psoriatic
Approved Indications in ChinaPsoriasis
Original Approved Country/TerritoryUnited States
Original Approved Date2016/03/22
Country/TerritoryCzechiaBelgiumBulgaria +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company (Ireland) LtdLilly Pharma LtdYale University +[9] 
Inactive CompaniesOregon Health And Science UniversityCatalent Pharma SolutionsThe Ohio State University +[4] 
Active IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisIdiopathic Subglottic Stenosis +[11] 
Inactive IndicationsPemphigoid, BullousPityriasis Rubra PilarisPyoderma Gangrenosum +[4] 

Other Information

ATC CodeL04AC13
Related LinksWikipediaDrugBankKEGG